With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavessvernakalant (Kynapid, MK-6621) to treat atrial fibrillation (AF) would not be sufficient to support resubmission of an...

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavessvernakalant to treat atrial fibrillation would not be sufficient to support resubmission of an NDA. On Monday,...

Cardiome granted Aspen exclusive rights to commercialize Cardiome’s IV Brinavessvernakalant in South Africa. The mixed ion channel antagonist is approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation...

Cardiome granted Logista rights to commercialize IV Brinavessvernakalant in Spain. Cardiome said financial terms were not disclosed, and Logista could not be reached. The mixed ion channel antagonist is approved in the EU for...

Cardiome said IV Brinavessvernakalant for atrial fibrillation (AF) is now available in Switzerland, the Czech Republic, Poland, Slovenia, Hungary, Latvia and Romania. Cardiome said Brinavess is already available in Austria. Last July, Cardiome granted...